摘要
目的:观察辛伐他汀治疗慢性心力衰竭的疗效与安全性。方法:入选138例慢性心力衰竭的患者,将其随机分为治疗组和对照组。对照组接受常规抗心力衰竭治疗,治疗组在常规治疗基础上加辛伐他汀20mg,1次/d,共治疗6月。治疗前后观察两组患者的心率、多普勒超声心动图检查左室射血分数(LVEF)、左室舒张末压内径(LVDd)及心功能情况。结果:治疗组显效39例,占26.5%;有效142例,占96.5%;对照组显效20例,占13.8%;有效127例,占86.39%。两组对比差异有统计学意义(P<0.05);治疗后两组之间心率、射血分数、左室舒张末期内径差异均有统计学意义(P<0.01)。结论:在接受心力衰竭常规治疗基础上加辛伐他汀对改善心力衰竭症状具有良好的作用。
Objective To determine the therapeutic benefits and safety of Simvastatin in the treatment of chronic heart failure. Method A total of 138 patients with chronic heart failure were split randomly into two groups （ the control groups and the treatment groups）. The control group received Standard treatment for chronic heart failure. In addition to this, the treatment group also received Simvastatin （20 mg）, once a day for 6 months. For all the patients, their heart rates were checked before and after this treatment. Their heart function, including LVEF and LVDD, was also monitored using Ultrasonic Doppler. Results For the treatment group, 39 cases （26.5%） showed significant improvement,while 142 cases （96.5%） showed improvement. For the control group, 20 cases （13.8%） showed significant improvement, while 127 cases （86.39%） showed improvement. There was statistically significant difference between the treatment and the control groups （ P 〈 0. 05 ）. After the 6 - month treatment ,the differences of heart rate, LVEF, and LVDD between the two groups were also found statistically significant （P 〈 0.01 ）. Conclusion This study demonstrated the therapeutic benefits of the addition of Simvastatin to the standard treatment for chronic heart failure.
出处
《吉林医学》
CAS
2008年第9期712-714,共3页
Jilin Medical Journal
